IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label COPAXONE. Show all posts
Showing posts with label COPAXONE. Show all posts
Thursday, 28 December 2017

The parlous state of national champions: the sagging fortunes of Teva

›
One of the darker aspects of hi-tech is the fate of national champions in smaller countries. When we say "fate", we typically m...
Thursday, 12 January 2017

When a company's future is caught in the generic drug/proprietary drug crosshairs

›
There is nothing in any other IP regime analogous to the generic/proprietary divide with respect to the exploitation of patent rights in ...
1 comment:
›
Home
View web version
Powered by Blogger.